Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve Medicamen Biotech Limited ....
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has informed the stock exchanges about a Board meeting scheduled for May 30, 2025. The Board will consider and approve the audited financial results (standalone and consolidated) for the quarter and full year ended March 31, 2025. It will also consider recommending a final dividend for FY2024-25. Additionally, the Board plans to appoint a new Cost Auditor (SPB & Co), Internal Auditor (Cheena & Associates), and Secretarial Auditor (AMJ & Associates, for a 5-year term). The trading window for company securities has been closed since April 1, 2025, and will reopen 48 hours after the results are announced.
This is a routine advance intimation ahead of the FY25 results announcement. Shareholders should watch for the audited numbers and any declared dividend on May 30. No material signals for the stock can be drawn until the actual results are disclosed.